Despite stopping semaglutide’s FLOW study in patients with type 2 diabetes and chronic kidney disease (CKD) early for efficacy on October 10, Novo Nordisk A/S has decided to buy another, differently acting, product for a similar use (Also see "The FLOW Of Novo Nordisk's Semaglutide Success Rolls Into Kidney Disease" - Scrip, 11 October, 2023.). It has bought the non-steroidal mineralocorticoid receptor antagonist (MRA) ocedurenone from KBP BioSciences Co Ltd for up to $1.3bn.
Novo Nordisk heeds KBP Biosciences’ CLARION call
Novo Nordisk’s metabolic juggernaut semaglutide is known to work in chronic kidney disease – but the group appears to want a back-up plan.
